



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Harry R. Davis, et al.

Examiner: To Be Assigned

Serial No.: 10/057,646

Group Art Unit: 1614

Filed: January 25, 2002

Atty. Docket No.: CV01379K

For: Combinations of Nicotinic Acid And  
Derivatives Thereof and Sterol  
Absorption Inhibitor(s) and  
Treatments for Vascular Indications

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☒ are attached ☐ were filed in related application U.S. Serial No(s) \_\_\_\_\_ filed \_\_\_\_\_, respectively.

(b) No fee is believed due because:

- ☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
- ☐ This Information Disclosure Statement is being concurrently filed with the above-identified application.
- ☐ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
- ☒ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

(c) ☐ This Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and


- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or

- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- (d) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 19-0395, Patent Case No. CV01379K.

Respectfully submitted,  
SCHERING-PLOUGH CORPORATION

Dated: January 8, 2004  
SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

By:


  
Name: **Ann M. Cannoni**  
Reg. No.: **35,972**  
**Attorney of Record**  
Telephone No.: (908) 298-5024

Attorney Docket No.: CV01379K

Application No.: 10/057,646

Filing Date: 01/25/2002

Inventor: Harry R. Davis et al.



PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no response is required to a collection of information unless it contains a valid OMB control number.

### Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

**Commissioner for Patents**

P.O. Box 1450

Alexandria, VA 22313-1450

on 01/08/2004

Date

Signature

Ann Marie Cannoni, Reg. No. 35,972

Typed or printed name of person of signing Certificate

**Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.**

Documents submitted:

Response Transmittal Form PTO/SB/21 - 1 Page


Information Disclosure Statement - 2 Pages

PTO-1449 - 1 pg. in dup.; (15) References

Certificate of Mailing PTO/SB92 - 1 Page

Post Card

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.:

CV01379K

APPLICATION NO.:

10/057,646

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APPLICANT:

Harry R. Davis et al.

FILING DATE:

01/25/2002

GROUP:

1614

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	6,030,990	02/29/00	Maeda et al.			
	AB	6,166,049	12/26/00	Smith et al.			
	AC	2003/0153541	08/14/03	Dudley et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
	AC	WO 01/14351 *	03/01/01	PCT				
	AD	WO 01/34148 *	05/17/01	PCT				
	AE	WO 01/60807 *	08/23/01	PCT				
	AF	WO 02/064094 *	08/22/02	PCT				
	AG	WO 02/08188 *	01/31/02	PCT				
	AH	WO 02/26729 *	04/04/02	PCT				
	AI	WO 03/039542 *	05/15/03	PCT				
	AJ	WO 03/074101 *	09/12/03	PCT				
	AK	WO 03/088962 *	10/30/03	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AL	Sorbera et al., Netoglitzazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139
	AM	Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259
	AN	Berger et al., Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology &amp; Therapeutics</i> , 2002, 4:163-174

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.